# TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

> **NCT06353360** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Healthy Life Innovation Medical Technology Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DEVICE:** Tumor Treating Fields
- **DRUG:** Tislelizumab
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT06353360
- **Lead sponsor:** Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-30
- **Primary completion:** 2025-07-15
- **Final completion:** 2026-03-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06353360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06353360, "TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06353360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*